OR WAIT null SECS
January 02, 2007
The closing presentation was perfectly pitched to bring a lump to our throats and have us cheering for fast-track drug development. I and 30 other journalists had spent the day touring a Big Pharma plant, and now sat shoulder to shoulder in a warm conference room, awaiting the final speaker.
Ninety million people live in California, Texas, New York, and Florida. Imagine that, sometime tonight, an unnameable catastrophe carries off everyone in those states over the age of 14. When the sun comes up tomorrow, only the children remain. Eighteen million children, left to care for one another or fend for themselves.
December 02, 2006
Poor support of drug- and process-development training programs will affect industry's future growth.
Years of concentrating its political support on one side of the political spectrum may have eroded the industry's ties to the new majority.
November 02, 2006
Yet again, FDA's ability to regulate drugs is under fire. At the core of this latest round of scrutiny is whether the agency has the resources to properly control the safety of new nanotech-based drug products.
The reason for reading the report is to inoculate ourselves against error.
November 01, 2006
While e-mail is quick and convenient, it's too easy to hide behind and, ultimately, faceless.
October 02, 2006
Much is riding on the market success or failure of Pfizer's Exubera inhalable insulin.
Teamwork, communication, and trust are as important as the technology.
September 02, 2006
I recently embarked on a quest: to investigate industry's use of the words, "generic" and "biosimilar" when describing a biologic molecule. An English major at heart, I was wrapped up in a news story that was partly about science, partly about words.